[go: up one dir, main page]

WO2009085226A3 - Inhibitors of cdc2-like kinases (clks) and methods of use thereof - Google Patents

Inhibitors of cdc2-like kinases (clks) and methods of use thereof Download PDF

Info

Publication number
WO2009085226A3
WO2009085226A3 PCT/US2008/013927 US2008013927W WO2009085226A3 WO 2009085226 A3 WO2009085226 A3 WO 2009085226A3 US 2008013927 W US2008013927 W US 2008013927W WO 2009085226 A3 WO2009085226 A3 WO 2009085226A3
Authority
WO
WIPO (PCT)
Prior art keywords
disorders
diseases
clk
cdc2
methods
Prior art date
Application number
PCT/US2008/013927
Other languages
French (fr)
Other versions
WO2009085226A2 (en
Inventor
Robert B. Perni
Jean Bemis
Joseph J. Nunes
Bruce G. Szczepankiewicz
Original Assignee
Sirtris Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sirtris Pharmaceuticals, Inc. filed Critical Sirtris Pharmaceuticals, Inc.
Publication of WO2009085226A2 publication Critical patent/WO2009085226A2/en
Publication of WO2009085226A3 publication Critical patent/WO2009085226A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C07D277/66—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Provided herein are compounds which are CDC2-Like Kinase (CLK) inhibiting compounds and methods of use thereof. The CLK-inhibiting compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, ocular disorders, and/or flushing as well as diseases or disorders that would benfit from increased mitochondrial activity. Also provided are compositions comprising a Clk-inhibiting compound in combination with another therapeutic agent.
PCT/US2008/013927 2007-12-21 2008-12-19 Inhibitors of cdc2-like kinases (clks) and methods of use thereof WO2009085226A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US896407P 2007-12-21 2007-12-21
US61/008,964 2007-12-21

Publications (2)

Publication Number Publication Date
WO2009085226A2 WO2009085226A2 (en) 2009-07-09
WO2009085226A3 true WO2009085226A3 (en) 2009-11-05

Family

ID=40386340

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/013927 WO2009085226A2 (en) 2007-12-21 2008-12-19 Inhibitors of cdc2-like kinases (clks) and methods of use thereof

Country Status (1)

Country Link
WO (1) WO2009085226A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010012010A (en) 2008-05-01 2010-11-30 Sirtris Pharmaceuticals Inc Quenolines and related analogs as sirtuin modulators.
CN102143957B (en) 2008-07-03 2014-08-20 西特里斯药业公司 Benzimidazoles and related analogs as sirtuin modulators
MX2011003372A (en) 2008-09-29 2011-06-09 Sirtris Pharmaceuticals Inc Chromenone analogs as sirtuin modulators.
WO2011041655A1 (en) 2009-10-01 2011-04-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Quinazolin-4-amine derivatives; and methods of use
ES2574927T3 (en) 2009-10-29 2016-06-23 Glaxosmithkline Llc Bicyclic pyridines and the like as modulators of sirtuin
WO2015093567A1 (en) * 2013-12-18 2015-06-25 国立大学法人京都大学 Pain-related compound and medicinal composition
US20170281607A1 (en) * 2016-04-01 2017-10-05 University Of Limerick Pharmaceutical compositions and methods for the treatment of diabetes
AR108325A1 (en) 2016-04-27 2018-08-08 Samumed Llc ISOQUINOLIN-3-IL CARBOXAMIDS AND PREPARATION AND USE OF THE SAME
US10722515B2 (en) * 2016-09-30 2020-07-28 Sri International Dual CLK/CDK1 inhibitors for cancer treatment
WO2020006115A1 (en) * 2018-06-26 2020-01-02 Betty Tam Methods of treating cancer using a clk inhibitor
WO2024220485A2 (en) * 2023-04-18 2024-10-24 The Regents Of The University Of California Dual inhibitors of dyrk1a and 5-ht2 for treating a brain disorder

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050171026A1 (en) * 2004-01-09 2005-08-04 Tokyo Medical And Dental University Therapeutic composition of treating abnormal splicing caused by the excessive kinase induction

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050171026A1 (en) * 2004-01-09 2005-08-04 Tokyo Medical And Dental University Therapeutic composition of treating abnormal splicing caused by the excessive kinase induction

Also Published As

Publication number Publication date
WO2009085226A2 (en) 2009-07-09

Similar Documents

Publication Publication Date Title
WO2009085226A3 (en) Inhibitors of cdc2-like kinases (clks) and methods of use thereof
WO2006105440A3 (en) Nicotinamide riboside and analogues thereof
WO2007102861A3 (en) Modulators of cdc2-like kinases (clks) and methods of use thereof
WO2009134973A8 (en) Quinolines and related analogs as sirtuin modulators
WO2006094209A3 (en) N-benzimidazolylalkyl-substituted amide sirtuin modulators
WO2006078941A3 (en) Novel sirtuin activating compounds and methods of use thereof
WO2010037127A8 (en) Chromenone analogs as sirtuin modulators
MY149316A (en) Sirtuin modulating imidazohiazole compounds
WO2006094210A3 (en) Tetrahydroquinoxalinone sirtuin modulators
IN2012DN03799A (en)
MX2009013977A (en) Sirtuin modulating thiazolopyridine compounds.
MX2011006555A (en) Thiazolopyridine sirtuin modulating compounds.
MX2010012961A (en) Imidazopyridine and related analogs as sirtuin modulators.
MX2010004965A (en) Amide derivatives as sirtuin modulators.
WO2007019344A8 (en) Imidazo [2,1-b] thiazole derivatives as sirtuin modulating compounds
MX2011006084A (en) Isoindolinone and related analogs as sirtuin modulators.
WO2006094246A3 (en) N-arylmethyl benzamide sirtuin modulators
WO2009061453A8 (en) Solubilized thiazolopyridines
WO2008100376A3 (en) Truncation variants of sirt1 and methods of use thereof
WO2008094737A3 (en) Purine compounds and compositions as kinase inhibitors for the treatment of plasmodium related diseases
WO2010029089A3 (en) Combination therapy for the treatment of diabetes and related conditions
WO2007130383A3 (en) Compositions and treatments using pyridazine compounds and secretases
WO2007022225A3 (en) Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof
WO2008033562A3 (en) Kinase inhibitor compounds
WO2008137619A3 (en) Thiazoles and pyrazoles useful as kinase inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08867162

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08867162

Country of ref document: EP

Kind code of ref document: A2